111 related articles for article (PubMed ID: 21498724)
1. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
Patta A; Fakih M
Anticancer Res; 2011 Mar; 31(3):975-8. PubMed ID: 21498724
[TBL] [Abstract][Full Text] [Related]
2. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
[TBL] [Abstract][Full Text] [Related]
3. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Mitry E; Baudin E; Ducreux M; Sabourin JC; Rufié P; Aparicio T; Aparicio T; Lasser P; Elias D; Duvillard P; Schlumberger M; Rougier P
Br J Cancer; 1999 Dec; 81(8):1351-5. PubMed ID: 10604732
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.
Habbel P; Kurreck A; Schulz CO; Regierer AC; Kaul D; Scholz CW; Neumann C; Possinger K; Eucker J
Anticancer Res; 2015 Sep; 35(9):5091-5. PubMed ID: 26254412
[TBL] [Abstract][Full Text] [Related]
7. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience.
Deutschbein T; Unger N; Yuece A; Eberhardt W; Gauler T; Lahner H; Mann K; Petersenn S
Horm Metab Res; 2011 Nov; 43(12):838-43. PubMed ID: 21989555
[TBL] [Abstract][Full Text] [Related]
10. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression.
Hamano Y; Moriwaki T; To K; Watahiki T; Yamada T; Sakashita S; Hyodo I
Intern Med; 2019 Apr; 58(8):1087-1091. PubMed ID: 30568142
[TBL] [Abstract][Full Text] [Related]
11. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
13. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Pectasides D; Samantas E; Fountzilas G; Briasoulis E; Kosmidis P; Skarlos D; Dimopoulos MA; Kalofonos HP; Economopoulos T; Syrigos K
Lung Cancer; 2007 Dec; 58(3):355-61. PubMed ID: 17698241
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
18. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Guan Y; Yao Q; Hao Y; Zeng X; Wang W; Gu X; Xiang J; Sun Y; Song Z
Cancer Med; 2023 Aug; 12(15):16011-16018. PubMed ID: 37351565
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]